<DOC>
	<DOCNO>NCT00582166</DOCNO>
	<brief_summary>Subjects receive Zevalin ( Ibritumomab Tiuxetan ) therapeutic regimen ; rituximab consolidation maintenance therapy every 3 month disease progression</brief_summary>
	<brief_title>Zevalin ( Ibritumomab Tiuxetan ) + Rituximab Maintenance</brief_title>
	<detailed_description>The objective study estimate median progression -free survival patient receive regimen , along rate complete response 6 month , toxicity associate regimen , laboratory correlate . Subjects receive Zevalin ( Ibritumomab Tiuxetan ) therapeutic regimen ; rituximab consolidation maintenance therapy every 3 month disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients biopsyproven nonhodgkins lymphoma follicular grade 1 , 2 , 3 Meeting FLIPI criterion intermediate high risk . No prior chemotherapy , radiotherapy immunotherapy lymphoma ; Patients may know HIV infection , must Hepatitis B Surface Antigen positive . May pregnant breastfeeding , document CNS disease , GCSF GMCSF within 2 week prior</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Zevalin , High Tumor Burden Indolent Non-Hodgkin 's Lymphoma</keyword>
</DOC>